Skip to main content
TipRanks
Go Ultimate75% OFF

Bioline Rx (BLRX) AI Stock Analysis

3 Followers
IL:BLRX

Bioline Rx

(TASE:BLRX)

Select Model
Rating:48Neutral
Price Target:ILA 1.00â–²(0.00% Upside)
Action:reiterated
Date:10/27/26

Overall score is held back primarily by very weak financial performance (collapsed TTM revenue, deep losses, and ongoing cash burn). Technicals are also unfavorable with the stock below major moving averages and negative MACD, though oversold signals provide a modest offset. The latest earnings call was comparatively constructive on clinical execution and runway into 1H 2027, which partially supports the score despite the early-stage and funding/dilution risks.

Positive Factors
Differentiated GLIX1 platformGLIX1 combines a differentiated mechanism with blood-brain barrier penetration and activity in glioblastoma models, addressing a severe unmet need. If clinical findings validate the preclinical profile, these attributes could support meaningful differentiation and broader partnering interest.
Negative Factors
Collapsed revenue and deep lossesThe sharp revenue decline and very negative net margin show that current commercial income is insufficient to support the company's operating base. This weak earnings profile increases dependence on milestones, royalties, partnerships, or external capital to sustain development.

Bioline Rx (BLRX) vs. iShares MSCI Israel ETF (EIS)

-60%-40%-20%0%20%40%IL:BLRX-44.44%EIS+9.50%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
ILS 29.87M
Dividend Yield
―
Average Volume (3M)
3.61M
Price to Earnings (P/E)
-1.0
Beta (1Y)
0.46
Revenue Growth
-93.07%
EPS Growth
62.25%
Country
Israel
Employees
22
Sector
General
Sector Strength
55
Industry
Biotechnology

Bioline Rx Business Overview & Revenue Model

Company Description

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatm...

How the Company Makes Money

BiolineRx generates revenue primarily through (1) collaboration/licensing arrangements and (2) to a lesser extent, other operating income typical of development-stage biotech companies. Under collaboration or licensing deals, the company may receive...

Bioline Rx Earnings Call Summary

Earnings Call Date:Aug 31, 2026(Q2-2026)|% Change Since:-33.33%|Next Earnings Date:May 27, 2025
Earnings Call SentimentPositive

The call was predominantly positive, driven by strong GLIX1 clinical recruitment and tolerability, encouraging preclinical efficacy and combination data, progress in the pancreatic cancer trial, APHEXDA royalty generation, and funding expected to support operations into the first half of 2027. These positives were tempered by the higher quarterly net loss and R&D spending, flat revenue, the early stage of GLIX1 clinical development, uncertainty surrounding the pancreatic cancer treatment landscape, and the commercial work still required to expand APHEXDA adoption.

Positive Updates

GLIX1 Clinical Trial Progressing Ahead of Plan
BioLineRx reported that recruitment to the Phase I/IIa GLIX1 trial in glioblastoma and other high-grade gliomas is going extremely well and that the trial continues to progress according to plan. Dosing began in the second of five planned Phase I cohorts last month, with the third cohort expected to begin dosing in September. The company has been pleased with GLIX1's safety and tolerability more than four months into the study and continues to anticipate Phase I data in the first half of 2027.

Negative Updates

Net Loss Increased Year Over Year
Net loss for the quarter ended June 30, 2026, was $4.3 million compared with $3.9 million in the 2025 quarter, an increase of $0.4 million, or approximately 10%.

Company Guidance

BioLineRx expects the third of 5 planned GLIX1 Phase I cohorts to commence dosing in September, with the Phase I part expected to recruit up to 30 patients and Phase I data anticipated in the first half of 2027; the Phase IIa expansion is planned to include additional cohorts, including GBM, newly diagnosed and/or recurrent, as well as additional cancers with or without standard of care, for example, PARP inhibitors. The CheMo4METPANC trial’s prespecified interim/futility analysis is planned for when 40% of progression-free survival events are observed, expected later this year. Cash and equivalents of $13.1 million are sufficient to fund the operating plan as currently contemplated into the first half of 2027, and the $3.75 million offering is expected to close later today.

Bioline Rx Financial Statement Overview

Summary

Weak fundamentals: TTM revenue is very small and down ~99% year over year, profitability remains deeply negative (TTM net margin about -572%), and cash flow is still meaningfully negative (TTM operating cash flow/free cash flow around -11M). Balance sheet leverage is moderate (debt-to-equity ~0.58) but declining equity/assets and negative ROE (~-47%) limit financial flexibility.

Income Statement

24Negative

Balance Sheet

45Neutral

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Mar 2025Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.40M1.28M28.94M4.80M00
Gross Profit976.95K462.21K19.68M1.11M00
EBITDA-11.31M-10.61M3.92M-57.09M-28.50M-24.07M
Net Income-8.04M-1.27M-9.22M-60.61M-20.75M-28.14M
Balance Sheet
Total Assets33.26M40.91M38.91M63.92M76.38M81.39M
Cash, Cash Equivalents and Short-Term Investments12.99M20.88M19.56M42.99M51.08M57.13M
Total Debt7.94M10.15M15.04M11.59M12.32M4.65M
Total Liabilities16.75M17.56M25.45M50.70M25.54M13.30M
Stockholders Equity13.68M18.20M13.46M13.22M50.84M68.09M
Cash Flow
Free Cash Flow-10.97M-8.77M-43.93M-22.91M-26.56M-23.67M
Operating Cash Flow-10.94M-8.74M-43.87M-22.61M-26.24M-23.57M
Investing Cash Flow12.53M-9.25M29.37M1.44M4.01M-38.22M
Financing Cash Flow-4.78M9.62M20.66M15.06M20.44M57.75M

Bioline Rx Technical Analysis

Technical Analysis SentimentNegative
Last Price1.00

Price Trends

50DMA1.20Negative
100DMA1.35Negative
200DMA1.41Negative

Market Momentum

MACD-0.06Negative
RSI35.69Neutral
STOCH90.91Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BLRX, the sentiment is Negative. The current price of 1.00 is below the 20-day moving average (MA) of 1.05, below the 50-day MA of 1.20, and below the 200-day MA of 1.41, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 35.69 is Neutral, neither overbought nor oversold. The STOCH value of 90.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BLRX.

Bioline Rx Risk Analysis

Bioline Rx disclosed 43 risk factors in its most recent earnings report. Bioline Rx reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Bioline Rx Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IL:BLRX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IL:BLRXIL:BLRX48NeutralILS 29.87M-1.00――-93.07%62.25%
IL:CANFIL:CANF38UnderperformILS 16.23M-0.23――――
IL:BOLTIL:BOLT27UnderperformILS 26.66M-2.19――-100.00%-29.02%

* General Sector Average

Performance Comparison

0%50000%100000%IL:BLRXIL:XTLBIL:CANFIL:BOLTIL:MTLFDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IL:BLRX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IL:BLRXBioLineRX Ltd.1.00-0.80-44.44%
IL:XTLBXTL Biopharmaceuticals Ltd.1.40-1.90-57.58%
IL:CANFCan-Fite BioPharma Ltd.258.90257.9025790.00%
IL:BOLTBioLight Life Sciences Ltd.293.60-100.80-25.56%
IL:MTLFMatricelf Ltd.246.80-161.20-39.51%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 27, 2026